⌕
Protagonist Therapeutics · PTGX · Nasdaq
Tenet 65 · Solid
Compare
$124.67−0.13%At closeTenet 65 · Solid
$124.67−0.16 (−0.13%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Protagonist Therapeutics (PTGX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 89% below its peak, net margin −282.8%. Worth your attention in FY25: Share count (+37.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼89.4%
46.0
FY21→FY25CAGR +13.9%/yr
Net income ($M)—
−130.1
FY21→FY25CAGR —
Free cash flow ($M)▼69.3%
56.1
FY21→FY25CAGR —
Diluted EPS—
−2.05
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+37.2%

46.3mn → 63.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$1.6M

+17.3% YoY in FY25 · 3.5% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)46.0Revenue0.0COGS−159.3R&D−44.9SG&A−158.1Op income28.0Tax & other−130.1Net income

-283¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -282.8% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
551,690.046,016.0434,433.060,000.026,581.027,357.0▼89.4%+13.9%
Cost of revenue
1,100.00.00.00.00.00.0——
Gross profit
550,590.0—A—A—A—A27,357.0——
Research & development
176,432.0159,290.0138,128.0120,161.0126,215.0126,006.0▲15.3%+6.0%
Selling, general & admin
51,063.044,853.043,462.033,491.031,739.027,196.0▲3.2%+13.3%
Total operating expenses
227,495.0204,143.0181,590.0153,652.0157,954.0153,202.0▲12.4%+7.4%
Operating incomefeeds ROC rank
323,095.0−158,127.0252,843.0−93,652.0−131,373.0−125,845.0——
Other income, net
27,153.028,816.026,565.014,697.03,980.0294.0——
Pretax income
350,248.0−129,311.0279,408.0−78,955.0−127,393.0−125,551.0——
Income tax
7,985.0838.04,220.00.00.0—▼80.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
342,263.0−130,149.0275,188.0−78,955.0−127,393.0−125,551.0——
Per share
Diluted EPSbuyback-sensitive
4.72−2.054.23−1.39−2.60−2.71——
Diluted shares (mn)
71.7363.5765.0856.7649.0446.32▼2.3%+8.2%
Margins
Gross margin99th pct in Healthcare
99.8%—A—A—A—A100.0%——
Operating margin
58.6%−343.6%58.2%−156.1%−494.2%−460.0%▼401.8pp+116.4pp
Net margin100th pct in Healthcare
62.0%−282.8%63.3%−131.6%−479.3%−458.9%▼346.2pp+176.1pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY14 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Protagonist Therapeutics' revenue last fiscal year?

Protagonist Therapeutics reported revenue of $46.0M in fiscal 2025, down 89.4% from fiscal 2024.

What was Protagonist Therapeutics' net income?

Protagonist Therapeutics reported net income of −$130.1M in fiscal 2025, a net margin of −282.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.